Inex Pharmaceuticals of Canada says that a majority note holder is demanding repayment of $24.6 million, saying the biotech is in default. Inex denies it is in default. The company owes $32.7 million in promissory notes originally issued to Elan and subsequently sold to institutional investors. Release